New Mail-Away DNA Test for Breast Cancer Worries Experts

When you want to learn about your heritage, mail-away DNA tests can be fascinating and fun. But when those tests supply information that can lead consumers to poor healthcare choices, experts become concerned. Such is the case with 23andMe’s direct-to-home genetic test for BRCA1/BRCA2, which recently was approved by the U.S. Food and Drug Administration (FDA). The move enables 23andMe to become the first company to market its cancer-risk test directly to the public without a prescription. The test reports on three variants in BRCA1/BRCA2 genes known to be associated with higher breast, ovarian and prostate cancers. “Simply spitting...

Read More